Search results
Results from the WOW.Com Content Network
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, [7] and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures; the name was changed to the current "Editas Medicine" two ...
For premium support please call: 800-290-4726 more ways to reach us
Since late 2011, Vertex has ranked among the top 15 best-performing companies on the Standard & Poor's 500. Vertex shares increased 250 percent in the same period. [9] In January 2014, Vertex completed its move from Cambridge, Massachusetts, to Boston, Massachusetts, and took residence in a new, $800 million complex. Located on the South Boston ...
The deal values each share of Alpine at $65, representing a premium of about 67% to the stock's close on Tuesday, a day before Bloomberg News reported that the company was considering options ...
Moderna (MRNA) stock is up 2.7% in Thursday's pre-market trading after the company inked a deal with Vertex Pharmaceuticals for the treatment of cystic fibrosis (CF) using gene editing.Moderna and ...
List of automotive fuel brands; List of bottle types, brands and companies; British Rail brand names; List of car audio manufacturers and brands; List of celebrity-branded perfumes; List of cigar brands; List of cigarette brands; List of defunct consumer brands; List of digital camera brands; Dunlop (brands) List of electronics brands; List of ...
The Billion-Dollar Molecule is a book [1] by journalist Barry Werth about the founding and early research efforts of the American biotechnology company Vertex Pharmaceuticals, which was founded in 1989 by Joshua Boger and was among the first biotechnology companies to adopt an explicit strategy of rational drug design as opposed to techniques based on combinatorial chemistry.
Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for the Treatment of People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation -Global ...